Phase 3 eXalt3 study shows significantly longer progression-free survival

(International Association for the Study of Lung Cancer) Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.